CorMedix (CRMD) Misses Q4 EPS by 69c

CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.16, $0.69 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $128.6 million versus the consensus estimate of $128.48 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Deutsche Bank Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Hold
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight